215 related articles for article (PubMed ID: 21889145)
1. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
Vergès B; Duvillard L; Brindisi MC; Gautier E; Krempf M; Costet P; Cariou B
Atherosclerosis; 2011 Nov; 219(1):342-8. PubMed ID: 21889145
[TBL] [Abstract][Full Text] [Related]
2. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
Chan DC; Wong AT; Pang J; Barrett PH; Watts GF
Clin Sci (Lond); 2015 Mar; 128(6):379-85. PubMed ID: 25291660
[TBL] [Abstract][Full Text] [Related]
3. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?
Chan DC; Lambert G; Barrett PH; Rye KA; Ooi EM; Watts GF
Clin Chem; 2009 Nov; 55(11):2049-52. PubMed ID: 19713274
[TBL] [Abstract][Full Text] [Related]
4. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
5. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.
Wassef H; Bissonnette S; Saint-Pierre N; Lamantia V; Cyr Y; Chrétien M; Faraj M
J Clin Lipidol; 2015; 9(5):664-75. PubMed ID: 26350813
[TBL] [Abstract][Full Text] [Related]
6. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
[TBL] [Abstract][Full Text] [Related]
7. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
[TBL] [Abstract][Full Text] [Related]
8. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
9. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
[TBL] [Abstract][Full Text] [Related]
10. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
[TBL] [Abstract][Full Text] [Related]
11. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients.
Kappelle PJ; Lambert G; Dullaart RP
Atherosclerosis; 2011 Feb; 214(2):432-5. PubMed ID: 21122860
[TBL] [Abstract][Full Text] [Related]
12. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756
[TBL] [Abstract][Full Text] [Related]
13. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
Jin K; Park BS; Kim YW; Vaziri ND
Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
[TBL] [Abstract][Full Text] [Related]
14. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
Kwakernaak AJ; Lambert G; Dullaart RP
Clin Biochem; 2012 Nov; 45(16-17):1522-4. PubMed ID: 22809551
[TBL] [Abstract][Full Text] [Related]
15. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects.
Kappelle PJ; Lambert G; Dahlbäck B; Nielsen LB; Dullaart RP
Atherosclerosis; 2011 Feb; 214(2):492-4. PubMed ID: 21122852
[TBL] [Abstract][Full Text] [Related]
16. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects.
Kwakernaak AJ; Lambert G; Muller Kobold AC; Dullaart RP
Thyroid; 2013 Feb; 23(2):166-72. PubMed ID: 23106476
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
Ouguerram K; Chetiveaux M; Zair Y; Costet P; Abifadel M; Varret M; Boileau C; Magot T; Krempf M
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1448-53. PubMed ID: 15166014
[TBL] [Abstract][Full Text] [Related]
18. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
20. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
Reyes-Soffer G; Pavlyha M; Ngai C; Thomas T; Holleran S; Ramakrishnan R; Karmally W; Nandakumar R; Fontanez N; Obunike J; Marcovina SM; Lichtenstein AH; Matthan NR; Matta J; Maroccia M; Becue F; Poitiers F; Swanson B; Cowan L; Sasiela WJ; Surks HK; Ginsberg HN
Circulation; 2017 Jan; 135(4):352-362. PubMed ID: 27986651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
